» Articles » PMID: 24387626

T1-mapping in the Heart: Accuracy and Precision

Overview
Publisher Elsevier
Date 2014 Jan 7
PMID 24387626
Citations 325
Authors
Affiliations
Soon will be listed here.
Abstract

The longitudinal relaxation time constant (T1) of the myocardium is altered in various disease states due to increased water content or other changes to the local molecular environment. Changes in both native T1 and T1 following administration of gadolinium (Gd) based contrast agents are considered important biomarkers and multiple methods have been suggested for quantifying myocardial T1 in vivo. Characterization of the native T1 of myocardial tissue may be used to detect and assess various cardiomyopathies while measurement of T1 with extracellular Gd based contrast agents provides additional information about the extracellular volume (ECV) fraction. The latter is particularly valuable for more diffuse diseases that are more challenging to detect using conventional late gadolinium enhancement (LGE). Both T1 and ECV measures have been shown to have important prognostic significance. T1-mapping has the potential to detect and quantify diffuse fibrosis at an early stage provided that the measurements have adequate reproducibility. Inversion recovery methods such as MOLLI have excellent precision and are highly reproducible when using tightly controlled protocols. The MOLLI method is widely available and is relatively mature. The accuracy of inversion recovery techniques is affected significantly by magnetization transfer (MT). Despite this, the estimate of apparent T1 using inversion recovery is a sensitive measure, which has been demonstrated to be a useful tool in characterizing tissue and discriminating disease. Saturation recovery methods have the potential to provide a more accurate measurement of T1 that is less sensitive to MT as well as other factors. Saturation recovery techniques are, however, noisier and somewhat more artifact prone and have not demonstrated the same level of reproducibility at this point in time.This review article focuses on the technical aspects of key T1-mapping methods and imaging protocols and describes their limitations including the factors that influence their accuracy, precision, and reproducibility.

Citing Articles

Radiomics for differential diagnosis of ischemic and dilated cardiomyopathy using non-contrast-enhanced cine cardiac magnetic resonance imaging.

Lasode J, Chantaksinopas W, Khongwirotphan S, Chattranukulchai P, Vorasettakarnkij Y, Sriswasdi S Radiol Med. 2025; .

PMID: 40063167 DOI: 10.1007/s11547-025-01979-z.


Substrates of Sudden Cardiac Death in Hypertrophic Cardiomyopathy.

Sclafani M, Falasconi G, Tini G, Musumeci B, Penela D, Saglietto A J Clin Med. 2025; 14(4).

PMID: 40004861 PMC: 11857077. DOI: 10.3390/jcm14041331.


Cardiac magnetic resonance imaging in patients with suspected myocarditis from immune checkpoint inhibitor therapy - A real-world observational study.

Lerchner T, Mincu R, Buhning F, Vogel J, Klingel K, Meetschen M Int J Cardiol Heart Vasc. 2025; 56:101581.

PMID: 39882168 PMC: 11775410. DOI: 10.1016/j.ijcha.2024.101581.


Boys With Duchenne Muscular Dystrophy Have Diastolic Dysfunction Based on CMR.

Starnes J, Weiner J, George-Durrett K, Crum K, Henderson C, Campbell M Circ Cardiovasc Imaging. 2024; 17(12):e017287.

PMID: 39629588 PMC: 11652209. DOI: 10.1161/CIRCIMAGING.124.017287.


Repeatability, Reproducibility, and Observer Variability of Cortical T1 Mapping for Renal Tissue Characterization.

Nowak M, Henningsson M, Davis T, Chowdhury N, Dennis A, Fernandes C J Magn Reson Imaging. 2024; 61(4):1914-1922.

PMID: 39468402 PMC: 11896918. DOI: 10.1002/jmri.29602.


References
1.
Schmitt P, Griswold M, Jakob P, Kotas M, Gulani V, Flentje M . Inversion recovery TrueFISP: quantification of T(1), T(2), and spin density. Magn Reson Med. 2004; 51(4):661-7. DOI: 10.1002/mrm.20058. View

2.
Lee J, Liu S, Nacif M, Ugander M, Han J, Kawel N . Myocardial T1 and extracellular volume fraction mapping at 3 tesla. J Cardiovasc Magn Reson. 2011; 13:75. PMC: 3269374. DOI: 10.1186/1532-429X-13-75. View

3.
Hunold P, Schlosser T, Vogt F, Eggebrecht H, Schmermund A, Bruder O . Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. AJR Am J Roentgenol. 2005; 184(5):1420-6. DOI: 10.2214/ajr.184.5.01841420. View

4.
Puntmann V, Voigt T, Chen Z, Mayr M, Karim R, Rhode K . Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013; 6(4):475-84. DOI: 10.1016/j.jcmg.2012.08.019. View

5.
Flett A, Hayward M, Ashworth M, Hansen M, Taylor A, Elliott P . Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010; 122(2):138-44. DOI: 10.1161/CIRCULATIONAHA.109.930636. View